Participated · Series C · Jul 2026

Founded in 2019 in San Sebastián, Multiverse Computing builds AI solutions inspired by quantum computing techniques—notably tensor-network approaches—to compress large language models and produce energy-efficient AI. The company says its technology can reduce model size and energy use by up to 95%, deliver 4x–12x faster inference, and cut costs by 50%–80%, enabling deployment on constrained devices like smartphones, laptops and satellites. Multiverse has launched a new generation of optimized models, including an open-source model and a family of compressed models designed for resource-limited environments. It has formed strategic partnerships with firms such as Cohere, Axelera AI, Plain Concepts, Inetum, EY and PwC to accelerate adoption in finance, energy, logistics, space, health and defense. Financially, Multiverse closed a €189M Series B in June 2025 (led by Bullhound Capital and including SETT and other investors) and is currently finalizing a larger round that could total €500M, backed in part by a €107M SETT commitment.

Led · Equity · Mar 2026

ONCOMATRYX has developed a proprietary Antibody-Drug Conjugate (ADC) platform focused on targeting Cancer-Associated Fibroblasts (CAFs) in the microenvironment of metastatic solid tumors. The company uses AI tools and Quantum Computing to assist in ADC design and candidate selection and employs proprietary payloads, dual payload strategies, and conjugation chemistry within its ADC+ platform. Its lead candidate, OMTX705, is undergoing clinical development (Phase Ib-II) with results planned for presentation at major oncology conferences in 2026, and OMTX105 is being prepared for clinical entry. ONCOMATRYX conducts collaborations with universities, hospitals and research centers in the US and Europe and is developing an ADC Fill & Finish facility in San Sebastián. The company recently raised $67 million from a mix of public and private investors to advance its clinical programs and expand its pipeline.